Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with NHS England for eligible sickle cell disease or SCD patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY (exagamglogene auto
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1397373446-0a7d68cba5fa4403a52568ea66413712.jpg "Easy Ways to Cut Rental Costs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1500845589-9354fc6166c6421f805e9c00863b992f.jpg "<div>ETFs are Booming—Here's What it Means for Your Retirement Plans</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2184518766-82ca48ba73184d84b51029d4907906c4.jpg "4 Surprising Ways Gen Z is Investing Differently Than Older Generations")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2160884476-2ea174a5709e491daa22f3ae4e30c059.jpg "The Most Expensive Airports in the U.S. Might Surprise You")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1036099056-ae3f5438b6af414dbb715ffaef0defc2.jpg "<div>Jeff Bezos' Estate Plan: What Is He Going To Do With All That Money?</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-13175326981-f4cb8eb62ac94fb895c145fa10467850.jpg "Is Your Credit Card Secretly Offering Free Roadside Assistance? Here’s How to Find Out")